Literature DB >> 19362962

IgM monoclonal gammopathy of undetermined significance and smoldering Waldenström's macroglobulinemia.

Robert A Kyle1, Joanne Benson, Dirk Larson, Terry Therneau, Angela Dispenzieri, L Joseph Melton Iii, S Vincent Rajkumar.   

Abstract

Immunoglobulin M monoclonal gammopathy of undetermined significance (IgM-MUS) was diagnosed in 213 Mayo Clinic patients who were residents of 11 counties in southeastern Minnesota from 1960 to 1994. During long-term follow-up, 29 (14%) developed non-Hodgkin lymphoma (n = 17), Waldenström's macroglobulinemia (WM; n = 6), chronic lymphocytic leukemia (n = 3), and AL amyloidosis (n = 3) with relative risks of 15-, 262-, 6-, and 16-fold, respectively. The cumulative probability of progression to one of these disorders was 10% at 5 years, 18% at 10 years, and 24% at 15 years, approximately 1.5% per year. Smoldering WM was identified in 48 patients at Mayo Clinic from 1974 to 1995. During follow-up, 33 of the 48 patients progressed to symptomatic WM. The median time to progression was 4.6 years. The risk of progression to WM was 6% at 1 year, 39% at 3 years, and 55% at 5 years.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19362962      PMCID: PMC3773469          DOI: 10.3816/CLM.2009.n.002

Source DB:  PubMed          Journal:  Clin Lymphoma Myeloma        ISSN: 1557-9190


  6 in total

1.  Prognostic validation of the international classification of immunoglobulin M gammopathies: a survival advantage for patients with immunoglobulin M monoclonal gammopathy of undetermined significance?

Authors:  Paolo G Gobbi; Luca Baldini; Chiara Broglia; Maria Goldaniga; Mario Comelli; Pierre Morel; Enrica Morra; Sergio Cortelazzo; Roberto Bettini; Giampaolo Merlini
Journal:  Clin Cancer Res       Date:  2005-03-01       Impact factor: 12.531

Review 2.  The spectrum of IgM monoclonal gammopathy in 430 cases.

Authors:  R A Kyle; J P Garton
Journal:  Mayo Clin Proc       Date:  1987-08       Impact factor: 7.616

Review 3.  Monoclonal gammopathy of undetermined significance, Waldenström macroglobulinemia, AL amyloidosis, and related plasma cell disorders: diagnosis and treatment.

Authors:  S Vincent Rajkumar; Angela Dispenzieri; Robert A Kyle
Journal:  Mayo Clin Proc       Date:  2006-05       Impact factor: 7.616

4.  A long-term study of prognosis in monoclonal gammopathy of undetermined significance.

Authors:  Robert A Kyle; Terry M Therneau; S Vincent Rajkumar; Janice R Offord; Dirk R Larson; Matthew F Plevak; L Joseph Melton
Journal:  N Engl J Med       Date:  2002-02-21       Impact factor: 91.245

5.  Long-term follow-up of IgM monoclonal gammopathy of undetermined significance.

Authors:  Robert A Kyle; Terry M Therneau; S Vincent Rajkumar; Ellen D Remstein; Janice R Offord; Dirk R Larson; Matthew F Plevak; L Joseph Melton
Journal:  Blood       Date:  2003-07-24       Impact factor: 22.113

6.  Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group.

Authors: 
Journal:  Br J Haematol       Date:  2003-06       Impact factor: 6.998

  6 in total
  11 in total

Review 1.  Immunomodulatory therapy to achieve maximum efficacy: doses, monitoring, compliance, and self-infusion at home.

Authors:  Mary Lucas; Ken Hugh-Jones; Angela Welby; Siraj Misbah; Peter Spaeth; Helen Chapel
Journal:  J Clin Immunol       Date:  2010-05       Impact factor: 8.317

2.  Robert Arthur Kyle, MD: a conversation with the editor.

Authors:  Robert Arthur Kyle; William Clifford Roberts
Journal:  Proc (Bayl Univ Med Cent)       Date:  2010-10

3.  Multiparameter flow cytometry for the identification of the Waldenström's clone in IgM-MGUS and Waldenström's Macroglobulinemia: new criteria for differential diagnosis and risk stratification.

Authors:  B Paiva; M C Montes; R García-Sanz; E M Ocio; J Alonso; N de Las Heras; F Escalante; R Cuello; A G de Coca; J Galende; J Hernández; M Sierra; A Martin; E Pardal; A Bárez; J Alonso; L Suarez; T J González-López; J J Perez; A Orfao; M-B Vidríales; J F San Miguel
Journal:  Leukemia       Date:  2013-04-22       Impact factor: 11.528

4.  CXCR4-targeted PET imaging using 64Cu-AMD3100 for detection of Waldenström Macroglobulinemia.

Authors:  Barbara Muz; Nilantha Bandara; Cedric Mpoy; Jennifer Sun; Kinan Alhallak; Feda Azab; Buck E Rogers; Abdel Kareem Azab
Journal:  Cancer Biol Ther       Date:  2019-10-01       Impact factor: 4.742

Review 5.  Diagnosis and management of Waldenström macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines.

Authors:  Stephen M Ansell; Robert A Kyle; Craig B Reeder; Rafael Fonseca; Joseph R Mikhael; William G Morice; P Leif Bergsagel; Francis K Buadi; Joseph P Colgan; David Dingli; Angela Dispenzieri; Philip R Greipp; Thomas M Habermann; Suzanne R Hayman; David J Inwards; Patrick B Johnston; Shaji K Kumar; Martha Q Lacy; John A Lust; Svetomir N Markovic; Ivana N M Micallef; Grzegorz S Nowakowski; Luis F Porrata; Vivek Roy; Stephen J Russell; Kristen E Detweiler Short; A Keith Stewart; Carrie A Thompson; Thomas E Witzig; Steven R Zeldenrust; Robert J Dalton; S Vincent Rajkumar; Morie A Gertz
Journal:  Mayo Clin Proc       Date:  2010-08-11       Impact factor: 7.616

Review 6.  Immunoglobulin M Monoclonal Gammopathies of Clinical Significance.

Authors:  Louis-Pierre Girard; Cinnie Yentia Soekojo; Melissa Ooi; Wee Joo Chng; Sanjay de Mel
Journal:  Front Oncol       Date:  2022-06-09       Impact factor: 5.738

7.  IgA and IgG hypogammaglobulinemia in Waldenström's macroglobulinemia.

Authors:  Zachary R Hunter; Robert J Manning; Christine Hanzis; Bryan T Ciccarelli; Leukothea Ioakimidis; Christopher J Patterson; Megan C Lewicki; Hsuiyi Tseng; Ping Gong; Xia Liu; Yangsheng Zhou; Guang Yang; Jenny Sun; Lian Xu; Patricia Sheehy; Massimo Morra; Steven P Treon
Journal:  Haematologica       Date:  2009-11-10       Impact factor: 9.941

Review 8.  Advances in the understanding of IgM monoclonal gammopathy of undetermined significance.

Authors:  Jonas Paludo; Stephen M Ansell
Journal:  F1000Res       Date:  2017-12-18

Review 9.  Monoclonal Gammopathy of Undetermined Significance (MGUS)-Not So Asymptomatic after All.

Authors:  Oliver C Lomas; Tarek H Mouhieddine; Sabrin Tahri; Irene M Ghobrial
Journal:  Cancers (Basel)       Date:  2020-06-12       Impact factor: 6.639

10.  Underlying IgM heavy chain amyloidosis in treatment-refractory IgA nephropathy: A case report.

Authors:  Hai-Ting Wu; Yu-Bing Wen; Wei Ye; Bing-Yan Liu; Kai-Ni Shen; Rui-Tong Gao; Ming-Xi Li
Journal:  World J Clin Cases       Date:  2019-10-06       Impact factor: 1.337

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.